Close

Cantor Fitzgerald Downgrades Applied Genetic Technologies Corp. (AGTC) to Hold

Go back to Cantor Fitzgerald Downgrades Applied Genetic Technologies Corp. (AGTC) to Hold

BMO Capital Cuts Price Target on Applied Genetic Technologies (AGTC) to $20

September 13, 2016 8:18 AM EDT

BMO Capital maintained an Outperform rating on Applied Genetic Technologies Corp. (NASDAQ: AGTC), and cut the price target to $20.00 (from $25.00), after updating estimates. BMO is now expecting data for XLRS in 2017 vs 2H16 previously as enrollment is slower-than-expected. The trial has enrolled 8/27 patients... More

Applied Genetic Technologies (AGTC) Tops Q4 EPS by 8c

September 12, 2016 4:23 PM EDT

Applied Genetic Technologies (NASDAQ: AGTC) reported Q4 EPS of $0.15, $0.08 better than the analyst estimate of $0.07. Revenue for the quarter came in at $12.1 million versus the consensus estimate of $12.93 million.

For earnings history and earnings-related data on Applied Genetic Technologies (AGTC) click here.

... More